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Abstract
Background: Myocardial perfusion imaging (MPI) can detect myocardial perfusion abnormalities but many examinations are
without pathological findings. This study examines whether circulating biomarkers can be used as screening modality prior
to MPI.
Methodology/Principal Findings: 243 patients with an intermediate risk of CAD or with known CAD with renewed
suspicion of ischemia were referred to MPI. Blood samples were analyzed for N-terminal fragment of the prohormone brain
natriuretic peptide (NT-proBNP), YKL-40, IL-6, matrix metalloproteinase 9 (MMP-9) and high sensitive C-reactive protein
(hsCRP). Patients with myocardial perfusion defects had elevated levels of NT-proBNP (p,0.0001), YKL-40 (p=0.03) and IL-6
(p=0.03) but not of hsCRP (p=0.58) nor of MMP-9 (p=0.14). The NT-proBNP increase was observed in both genders
(p,0.0001), whereas YKL-40 (p=0.005) and IL-6 (p=0.02) were elevated only in men. A NT-proBNP cut off-concentration at
25 ng/l predicted a normal MPI with a negative predictive value .95% regardless of existing CAD.
Conclusions: 20-25% of patients suspected of CAD could have been spared a MPI by using a NT-proBNP cut-off
concentration at 25 ng/l with a negative predictive value .95%. NT-proBNP has the potential use of being a screening
marker of CAD before referral of the patient to MPI.
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Introduction
In patients with possible symptoms of coronary artery disease
(CAD) it is important not only to detect patients with the disease
but at the same time to identify patients with no CAD. Myocardial
perfusion imaging (MPI) can be used to demonstrate myocardial
perfusion abnormalities in patients with and without known CAD
[1–3] and to evaluate the risk of new cardiac events in patients
with known or intermediate risk of CAD [4,5]. In daily clinical
practice 35–65% of all MPIs are without perfusion defects despite
symptoms of myocardial ischemia [6–8]. Considering the
radiation dose and the significant costs of a MPI, it could be of
considerable importance if biomarkers can be used as a screening
modality before referral to MPI.
Recently, high sensitivity C-reactive protein (hsCRP) levels have
been found in patients with myocardial perfusion abnormalities
[9]. CRP is the most examined inflammation marker in relation to
cardiovascular disease (CVD) and substantial evidence indicates
that baseline hsCRP level is an independent predictor of
cardiovascular events both in patients with non-fatal myocardial
infarction (MI) and in apparently healthy individuals [10,11].
Similarly, two recent prospective studies and a meta-analysis of
previous studies have shown, that interleukin 6 (IL-6), a proximal
mediator of CRP, are associated with risk of CAD about as
strongly and in addition to established risk factors [12]. Moreover,
the heart failure biomarker N-terminal of the pro-hormone brain
natriuretic peptide (NT-proBNP) also has diagnostic and prog-
nostic importance in terms of cardiovascular events and mortality
in patients with stable angina pectoris and in patients with acute
coronary syndrome [13–15]. However, the clinical consequences
of elevated NT-proBNP levels are not fully elucidated and
concomitantly new markers with different pathophysiological
approaches emerge. YKL-40 is a marker of inflammation and
endothelial dysfunction, and matrix metalloproteinase 9 (MMP-9)
belongs to an enzyme family specialized in breaking down con-
stituents of the extracellular matrix. YKL-40 protein expression is
found in vivo in both macrophages and vascular smooth muscle
cells in the atherosclerotic plaque where it seems to participate in
processes during early stages of atherosclerosis by promoting the
process of the atherosclerotic plaque formation [16]. The major
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and vascular smooth muscle cells [17], and MMP-9 seems to be
one of the predominant MMPs within the vulnerable plaque,
where it promotes plaque progression and destabilization [18,19].
Both YKL-40 and MMP-9 therefore appear to be associated
with the early pathophysiology of atherosclerosis. Furthermore,
YKL-40 is associated with the presence and extent of coronary
artery disease (CAD) [20–22] and elevated YKL-40 levels are
seen in patients with myocardial infarction (MI) [22,23]. Serum
MMP-9 levels are gradually increasing with progressing coronary
ischemic symptoms [24] and might be useful as an index marker
of plaque activity in patients with known CAD [25].
The objective of the present study was to examine whether these
markers alone or in combination could be used as a screening
modality in patients suspected of CAD prior to referring to MPI.
Results
Baseline demographic, medical history and paraclinical vari-
ables in relation to gender are presented in Table 1. There was an






N 243 118 125 NS
Age
* 61.0611.5 60.9611.2 61.2611.9 NS
Smoking 68 (28.0) 39 (33.1) 29 (23.2) NS
Diabetes 30 (12.3) 14 (11.9) 16 (12.8) NS
Hypertension 96 (39.5) 43 (36.4) 53 (42.4) NS
Prior myocardial infarction (MI) 49 (20.2) 31 (26.3) 18 (14.4) 0.002
Prior revascularisation (revasc.) 19 (12.8) 14 (9.7) 5 (2.9) ,0.001
Known CAD (MI or revasc.) 68 (28.0) 45 (38.1) 23 (18.4) ,0.001
Medication:
Beta-blockers 121 (49.8) 66 (55.9) 55 (44.0) NS
Calcium antagonists 49 (20.2) 24 (20.3) 25 (20.0) NS
ACE-inhibitors 80 (32.9) 43 (36.4) 37 (29.6) NS
Diuretics 79 (32.5) 35 (29.7) 44 (35.2) NS
Statins 111 (45.7) 67 (56.8) 44 (35.2) ,0.001
Paraclinic:
Body Mass Index
* 27.764.9 28.364.3 27.265.4 NS
Resting heart rate, bpm
* 74.0612.9 72.1612.5 75.8613.1 0.02
Systolic blood pressure, mmHg* 146623 146622 147625 NS
Diastolic blood pressure, mmHg* 87613 88613 86613 NS
Creatinine, mmol/l
* 83621 93618 75619 ,0.001
Total cholesterol, mmol/l
* 5.361.3 5.261.3 5.461.2 NS
HDL, mmol/l
* 1.560.5 1.3660.4 1.760.6 ,0.001
LDL, mmol/l
* 3.061.1 3.061.2 3.161.0 NS
Stress type at MPI:
Ergometer exercise 132 (54.3) 72 (61.0) 60 (48.0) NS
Dypyridamole 105 (43.2) 43 (36.4) 63 (50.4) ,0.001
Dobutamine stress 6 (2.5) 3 (2.5) 3 (2.4) NS
Heart dimensions, post stress:
EF, % ** 64 (57–70) 59 (51–64) 68 (64–74) ,0.001
EF , lower normal limit*** 19 (7.8) 12 (10.2) 7 (5.6) ,0.001
ESV index , lower normal limit, ml/m
2 0 (0.0) 0 (0.0) 0 (0.0) NS
Results of MPI:
Normal MPI 199 (81.9) 84 (71.2) 115 (92.0) ,0.001
Abnormal MPI 44 (18.1) 34 (28.8) 10 (8.0) ,0.001
*Mean (SD),
**median (IQR), otherwise presented as N (%).
1Percentage within the total population,
2percentage within gender,
3p value for comparison between genders.
Abbreviations: bpm, beats pr. minute; CAD, coronary artery disease; EF, ejection fraction; ESV index, end systolic volume index; MPI, myocardial perfusion imaging.
doi:10.1371/journal.pone.0014196.t001
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between genders.
There were no differences in systolic and diastolic blood
pressure, prevalence of hypertension or diabetes or otherwise use
of medication between genders. Although women had higher
HDL levels than men, there was no difference in total cholesterol
levels. A higher prevalence of CAD was seen in the male part of
the population where a higher proportion of treatment with statins
also were seen.
An equal number of men and women were capable of
performing the bicycle ergometer test, but significantly more
women than men were stressed with dypyridamole. Only 19
(7.8%) patients, more men than women, had a low post stress EF
but none of these had ESV index below lower normal limit.
Myocardial perfusion defects were found in 44 (18.1%) patients,
more often in men than in women (p,0.001).
Biomarker levels according to outcome of MPI are shown in
Table 2. NT-proBNP levels were elevated in patients with
myocardial perfusion defects (p,0.001). This was found for both
men and women. YKL-40 and IL-6 levels were significantly
elevated in patients with myocardial perfusion defects but only in
men (p=0.005 and p=0.02, respectively). MMP-9 and hsCRP
levels were not elevated in patients with myocardial perfusion
defects neither when looking at the genders separately.
Biomarker levels according to history of CAD are shown in
Table 3. NT-proBNP levels were elevated in patients with known
CAD (p,0.0001) both in men (p,0.0001) and women (p=0.003).
However, significantly higher NT-proBNP levels were observed in
patients with an abnormal MPI when compared to patients with
known CAD (264 (109–929) ng/l vs. 111 (54–378) ng/l,
p,0.0001). There were not significantly higher biomarker levels
of any of the other biomarkers in patients with known CAD when
compared to patients without (all p values .0.09).
Using ROC-analyses on NT-proBNP levels for the prediction of
a normal MPI, a sensitivity of more than 95.5 (95.2–95.7)% was
obtained at a NT-proBNP concentration ,25 ng/l in the total
population (Figure 1). A total of 42 individuals (21.1%) had a NT-
proBNP concentration ,25 ng/l but only 2 of these (4.5%) had
myocardial perfusion defects. When looking at the genders
separately, the sensitivity of a NT-proBNP concentration
,25 ng/l as a predictor of a normal MPI was 92.1 (91.8–
93.2)% in men (Figure 2) and 100 (97.3–100)% in women
(Figure 3). Observed, only 2 of 27 men (7.4%) and 0 of 15 women
(0.0%) with a NT-proBNP concentration ,25 ng/l had myocar-
dial perfusion defects. Similar ROC curve analyses in subgroups of
patients with or without a history of CAD reveal negative
predictive values of NT-proBNP 95 ng/ml (sensitivity 96 (95.2–
96.9)%) ,25 ng/ml (sensitivity 90 (89.3–90.6)%), respectively
(curves not shown).
Furthermore, only 5% of the women with a NT-proBNP level
,250 ng/l had myocardial perfusion defects equal to a NT-
proBNP cut-off concentration of 250 ng/l as a predictor of a
normal MPI with a negative predictive value of 95 (84–100)%.
Same result is seen in the subgroup of women with known CAD
where 4 of 88 women (4.5%) with a NT-proBNP level ,250 ng/l
had myocardial perfusion defects and that equals a negative
predictive value of 95.5 (79.8–100)%.
Univariate regression analyses showed that NT-proBNP levels
were correlated with a pathological outcome at MPI (r
2=0.53,
p,0.001). This association was not attenuated in multivariate
analyses after adjustment for age, gender, smoking, cholesterol
Table 2. Biomarker levels according to outcome of MPI.
Normal MPI Abnormal MPI p value
Total study population, N 199 44
NT-proBNP, ng/l 59 (28–143) 264 (109–929) ,0.001
YKL-40, ng/ml 51 (34–80) 67 (40–97) 0.03
IL-6, pg/ml 1.9 (1.2–2.8) 2.2 (1.6–4.0) 0.03
MMP-9, ng/ml 124 (81–183) 146 (82–220) 0.14
hsCRP, mg/l 2.0 (1.4–4.0) 2.2 (1.4–3.8) 0.58
Male population, N 84 34
NT-proBNP, ng/l 44 (13–82) 279 (102–948) ,0.001
YKL-40, ng/ml 48 (33–71) 67 (51–110) 0.005
IL-6, pg/ml 1.8 (1.3–2.7) 2.3 (1.5–5.1) 0.02
MMP-9, ng/ml 125 (91–174) 147 (84–218) 0.21
hsCRP, mg/l 1.8 (1.4–3.7) 2.2 (1.4–3.7) 0.43
Female population, N 115 10
NT-proBNP, ng/l 83 (41–167) 226 (124–1330) ,0.001
YKL-40, ng/ml 55 (35–88) 39 (33–66) 0.35
IL-6, pg/ml 1.9 (1.1–2.9) 2.1 (1.6–2.6) 0.86
MMP-9, ng/ml 121 (75–197) 130 (76–268) 0.47
hsCRP, mg/l 2.1 (1.4–4.1) 2.4 (1.4–5.2) 0.97
Presented as median (interquartile range). N, number; MPI, myocardial
perfusion imaging; NT-proBNP, N-terminal fragment of the prohormone brain
natriuretic peptide; IL-6, interleukine 6; MMP-9, matrix metalloproteinase 9;
hsCRP, high sensitive C-reactive protein.
doi:10.1371/journal.pone.0014196.t002
Table 3. Biomarker levels according to known coronary
artery disease (CAD; prior myocardial infarction or
revascularisation).
No CAD CAD p value
Total study population, N 175 68
NT-proBNP, ng/l 60 (25–153) 111 (54–378) ,0.001
YKL-40, ng/ml 51 (33–80) 59 (43–97) 0.02
IL-6, pg/ml 1.9 (1.2–2.9) 2.2 (1.3–3.2) 0.27
MMP-9, ng/ml 132 (77–186) 127 (91–189) 0.13
hsCRP, mg/l 2.1 (1.4–4.1) 2.2 (1.4–3.8) 0.43
Male population, N 73 45
NT-proBNP, ng/l 42 (10–94) 104 (49–488) ,0.001
YKL-40, ng/ml 50 (32–80) 56 (44–86) 0.16
IL-6, pg/ml 1.8 (1.3–3.3) 2.1 (1.4–3.2) 0.71
MMP-9, ng/ml 132 (84–188) 133 (105–183) 0.19
hsCRP, mg/l 1.8 (1.4–3.8) 2.1 (1.4–3.7) 0.92
Female population, N 102 23
NT-proBNP, ng/l 87 (36–168) 139 (71–300) 0.03
YKL-40, ng/ml 54 (34–80) 64 (38–176) 0.09
IL-6, pg/ml 1.9 (1.1–2.7) 2.3 (1.0–3.5) 0.38
MMP-9, ng/ml 128 (75–183) 100 (80–240) 0.47
hsCRP, mg/l 2.3 (1.5–4.3) 1.7 (1.2–3.2) 0.31
Presented as median (interquartile range). N, number; MPI, myocardial
perfusion imaging; NT-proBNP, N-terminal fragment of the prohormone brain
natriuretic peptide; IL-6, interleukine 6; MMP-9, matrix metalloproteinase 9;
hsCRP, high sensitive C-reactive protein.
doi:10.1371/journal.pone.0014196.t003
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doi:10.1371/journal.pone.0014196.g001
Figure 2. ROC-curve of NT-proBNP values in the prediction of a normal MPI in men (total population).
doi:10.1371/journal.pone.0014196.g002
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r
2=0.57, p,0.001). In univariate analyses, no association was
found between myocardial perfusion defects and levels of YKL-40
(p=0.50), IL-6 (p=0.19), MMP-9 (p=0.10) or hsCRP (p=0.74).
Discussion
The main results of the present study are that levels of NT-
proBNP, YKL-40 and IL-6 are elevated in patients with symptoms
of CAD and myocardial perfusion defects. NT-proBNP levels are
elevated in both genders whereas levels of YKL-40 and IL-6 are
elevated only in men. Using NT-proBNP ,25 ng/l as discrim-
inatory value the negative predictive value was .95% with
corresponding values for men being 92% and 100% for women. In
the subgroup of patients with or without known CAD, the negative
predictive value was 96% and 90%. Using a discriminatory value
for NT-proBNP ,25 ng/l, 21.1% of the MPIs in the total
population and 25.3% in patients without known CAD, could
have been spared the MPI if relying on NT-proBNP measurement
prior to the stress test. It does not seem to be the patients with
known CAD who are responsible for this outcome, since patients
with myocardial perfusion defects have significant higher NT-
proBNP levels. On the basis of these findings, NT-proBNP
measurement prior to an MPI could probably be used as a useful
gate-keeper test since the finding of few abnormal MPIs suggest a
relatively low pre test likelihood for ischemic heart disease in the
study population although the population either has CAD or has
an intermediate risk of CAD. The difference of the negative
predictive value of NT-proBNP between the genders could
probably be explained by association between NT-proBNP levels
and severity of CAD. It is also well-known, that despite similar risk
factors men develop atherosclerosis earlier in life and with a higher
incidence than women [26,27]. However, we have not examined
the severity of CAD in the present study, so this remains purely
speculative, but we the age between the genders did not differ
significantly but we could document 3 times as many men than
women with a history of CAD (62% vs. 23%).
Although the predominant pathophysiological process underly-
ing increased circulating levels of NT-proBNP is regional and
global impairment of left ventricular systolic or diastolic function
leading to increased left ventricular wall stretch, recent studies
have suggested that ischemia itself promotes release of BNP
[28,29]. The responsible mechanisms still remain to be fully
elucidated, but both experimental and clinical myocardial
infarction is associated with gradual and sustained elevation of
circulating BNP levels [29] and cardiac BNP expression as verified
by cardiac biopsies of hypoxic ventricular areas is of the same
magnitude in patients with CAD and with normal left ventricular
function as in patients with congestive heart failure but no
myocardial ischemia [29]. Furthermore, NT-proBNP has emerged
as a potential tool in the diagnosis and therapy of CVD besides
heart failure [13,15,30]. NT-proBNP concentrations are found to
be a prognosticator of long-tem mortality in patients with stable
CAD [14], of subsequent MI in patients with unstable CAD [31]
and of short term cardiac risk in patients with ACS [32,33].
Finally, NT-proBNP concentrations below the thresholds used to
diagnose heart failure have been found to be associated with an
increased mortality risk and risk of cardiovascular events in
individuals without heart failure [30].
Our finding of an independent correlation between NT-
proBNP and myocardial perfusion defects (reversible and
irreversible) supports that high NT-proBNP levels also could be
predictive of reversible respectively irreversible myocardial
perfusion defects at specific concentration intervals. This is in
Figure 3. ROC-curve of NT-proBNP values in the prediction of a normal MPI in women (total population).
doi:10.1371/journal.pone.0014196.g003
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biomarkers including NT-proBNP substantially improve the risk
stratification and prediction of cardiovascular death in individuals
with and without CVD [34]. However, this is contradicted by a
larger study which investigated the usefulness of NT-proBNP as a
predictive marker of angiographic ally significant CAD and CAD
severity, where NT-proBNP could not predict significant angio-
graphic lesions following inclusion of traditional risk factors [35].
This objective is investigated further in current studies of our
research group.
The overall increased YKL-40 concentration in patients with
myocardial perfusion defects was primarily due to elevated YKL-
40 levels in men, a difference that cannot be explained by gender
differences [36]. Our results are in agreement with previous studies
showing that elevated YKL-40 levels are independently associated
with the presence [20–22] and extent [20] of CAD. Moreover, in
patients with MI even higher YKL-levels are documented [22,23].
YKL-40 has also been found to be associated with all-cause as well
as cardiovascular mortality not only in patients with stable CAD
[22] but also in the general population above 50 years of age
without known diabetes or CAD [37]. In patients with type 1
diabetes, increasing YKL-40 levels are seen with increasing levels
of albuminuria as an expression of progressing vascular damages
in the kidneys, suggesting that YKL-40 might be used as an early
marker of CVD [38]. However, the present findings do not
support this hypothesis.
The association between elevated IL-6 levels and myocardial
perfusion defects in the present study are in accordance with a
meta-analysis where IL-6 levels are associated with risk of CAD
[12] but the causality between IL-6 and CAD remains uncertain.
In contrast to the single previous study also designed to examine
hsCRP levels in patients referred to a MPI [9], the present study
could not document elevated hsCRP levels in patients with
myocardial perfusion defects. This divergence could be due to a
significantly minor study population (N=127) with a higher
prevalence of men (62%) in the previous study but also due to a
study population with less cardiovascular disease. Despite existing
knowledge about the role of hsCRP and IL-6 in terms of CAD
[11,12,18], other studies are not so convincing [10,39]. Our
findings regarding hsCRP and IL-6 are in accordance with a
previous study where no association was found between levels of
hsCRP or IL-6 and angiographic severity and major cardiac
events [39]. In the present study, the explanation for elevated IL-6
levels in men but not in women remains speculative, but might
reflect some kind of local production in the heart (whereas CRP is
primarily produced by the liver).
We did not find elevated MMP-9 levels in patients with
myocardial perfusion defects although MMP-9 is known to
destabilize the advanced atherosclerotic plaques [19] and are seen
with elevated concentrations in patients with increasing severity of
ischemic symptoms [24,40].
Beside the limitation of being a small-scale study, the foremost
limitation is the lack of a pre-test likelihood analysis of the risk of
CAD or an abnormal MPI in the study population. One could also
dispute the relative high proportion of normal MPIs in this study
but in comparison to other studies this is most likely due to the
more selected group of participants with less co-morbidity. The
advantage of having participants with less co-morbidity is that the
NT-proBNP cut-off concentration as a predictor of a normal MPI
is strengthened. Furthermore, the small number of participants
above 70 years of age (44 individuals of which 13 had an abnormal
MPI) make statistical analyses of the influence of age on the
predictive value of NT-proBNP obsolete due to lack of statistical
power.
We believe the finding of this preliminary study indicates, that
NT-proBNP could be used as a screening marker and to be an
indicator of a normal MPI when below a certain threshold. This
result could be used in the clinical setting in primary care but also
at specialized departments of cardiology in the hospital setting
before referring a patients to MPI. However, such screening
method should never be used alone, but is thought of as a
complement in the risk stratification of coronary artery disease and
should always be weighed against other risk factors of coronary
artery disease. Finally, from a socio-economic perspective the cost
of a NT-proBNP analysis is approximately $18, whereas a MPI
costs a minimum of approximately $620 but 40% more if
pharmacological stress is used (rates at Copenhagen University
Hospital Herlev, Denmark). Therefore, beside the patient-
orientated clinical aspect, there is also a significant economic
aspect which should not be ignored.
This study shows that in patients suspected of CAD, NT-
proBNP could possibly demarcate a subgroup of patients without
myocardial perfusion defects due to coronary artery stenosis
causing reduced blood flow. YKL-40, IL-6, MMP-9 and hsCRP
were unable to do so. The prognostic importance of these markers
may therefore be their ability to indicate the presence of
vulnerable coronary artery plaques, and thereby play an important
role in other clinical settings.
The present techniques available to detect the presence/
absence of coronary plaques are all either relatively costly, with
a not negligible radiation dose or invasive. Although effective, they
could appropriately be accompanied by a cheap and easy
screening method without major side effects. The clinical
implication of the present study is that 20–25% of patients
suspected of CAD could have been spared a MPI through the
measurement of NT-proBNP in a single blood sample prior to
MPI. By using a cut-off concentration of NT-proBNP ,25 ng/l
and by accepting a negative predictive value of minimum 95% for
a normal MPI up to 25% of the normal background population
with symptoms of cardiac ischemia referred to a MPI could have
been spared this examination.
However, replication of our findings in large-scale studies is
needed before using NT-proBNP as a screening marker for
normal MPI in the clinical setting. In this context, the importance
of inflammation markers like YKL-40, IL-6, MMP-9 and hsCRP
should evaluated due to their significant role in the early part of




Informed written consent was obtained from all participants
before participation. The study was approved by the local ethics
committee of Copenhagen (H-B-2007-058) and investigations
conformed to the principles of The Helsinki Declaration.
Study population
The study population consisted of 243 consecutive referred
patients from either a private full time practicing cardiologist or
from Dep. of Cardiology, Copenhagen University Hospital
Herlev, to an MPI at Dep. of Clinical Physiology, Copenhagen
University Hospital Herlev, during the period November 2005 to
November 2007.
Patients were referred to MPI either if they were considered to
have an intermediate risk of having CAD (symptoms of transient
chest pain and/or worsening of chest pain when exercising and/or
transient referred pain to the upper limbs or neck) or had a history
NT-proBNP as a Screening Tool
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clinically examined and included consecutively. Patients with
ongoing infectious disease or other concomitant diseases (known
chronic obstructive pulmonary disease, cancer, rheumatic or
connective tissue disease) as well as patients with reduced renal
function (serum creatinine .200 mmol/l) were not included in the
study, since inflammation markers, especially YKL-40 levels, are
affected in these conditions.
All participants underwent a clinical examination including an
ECG and a medical history was obtained and medications were
recorded before referral to MPI. The following patient baseline
characteristics were registered: History with CAD (previous
myocardial infarction (episode with elevated plasma coronary
markers and ECG verified myocardial infarction) or coronary
revascularization (percutaneous coronary intervention (PCI) and
coronary bypass grafting (CABG)), heart failure, hypertension,
defined as either systolic blood pressure $140 mm Hg, diastolic
blood pressure $90 mm Hg or use of antihypertensive medicine.
Measurements
A light caffeine-free meal was allowed prior to MPI. Blood
samples were drawn following 15 min of rest in sitting position on
the same day as the MPI but prior to this. Routine analyses were
performed and the following markers were tested: 1) Plasma NT-
proBNP, using a solid double antibody sandwich technique with
chemiluminescense as signal (Immulite 2500, Siemens Healthcare
diagnostics, Deerfield, IL, USA).Measuring range was ,20–
35000 ng/l with intra- and interassay coefficients of variation
both ,5.0% (Low-end reproducibility of NT-proBNP from daily
internal quality assessment with low control (nominal concentra-
tion 30 ng/L) was 7%, in harmony with the ‘‘low level between
laboratory precision profile’’ from UKNEQAS Cardiac Marker
External Quality Assessment Service). Siemens Immulite 2500 and
Roche Elecsys 2010 use the same assay for NT-proBNP with a
mean linear conversion factor between the methods of Y=0.97
X+26 ng/L, r=0.99; 2) Plasma YKL-40, using an ELISA method
(Quidel, USA). Measuring range of the assay was 20–300 ng/ml,
with intra- and interassay coefficients of variation of 5.8% and
6.0%, respectively; 3) IL-6, using a high sensitive ELISA (R&D
Systems, USA). Lower detection limit was 0.04 pg/ml and intra-
and interassay coefficients of variation was 7.4% and 7.8%,
respectively; 4) MMP-9, using an ELISA (R&D Systems, USA).
Lower detection limit was 0.16 pg/ml and intra- and interassay
coefficients of variation was 2.3% and 7.5%, respectively; and 5)
CRP, using a highly sensitive, latex-particle-enhanced immuno-
turbidimetric assay (DAKO, Glostrup, Denmark) with a measur-
ing range of 0.2–80 mg/L and with a lower detection limit of
0.03 mg/L. The results of biomarker analyses were not known
when the MPI was done.
Exercise testing
The stress test was performed as a symptom-limited bicycle
exercise test (n=132). In patients unable to perform physical
exercise or did not reach at least 85% of expected heart frequency
maximum (220 beats/min – age) a pharmacological stress with
dypyridamole/dobutamine was performed according to a stan-
dard protocol (n=111).
The exercise was performed on a bicycle ergometer according
to a standard protocol with 25 W increase every second minute.
Heart rate, blood pressure and a 12-lead ECG were recorded
continuously. A horizontal or down sloping ST-segment depres-
sion of at least 1 mm 80 ms after the J-point compared to rest
ECG was considered significant for myocardial ischemia. Angina
pectoris was defined as chest pain emerging during exercise with
relief during recovery or by treatment with nitroglycerin. Injection
of 700 MBq
99mTc-sestamibi was given at peak exercise level one
minute prior to termination of exercise. Criteria for ending the test
were fatigue, dyspnoea, angina, ventricular tachycardia, or a
decline in systolic blood pressure of more than 20 mmHg during
exercise.
Acquisition and Image Analysis
The myocardial perfusion stress images were obtained one hour
after injection. A two-day protocol was applied starting with stress
images followed by acquisition of rest images within a week. The
images were acquired using a rotating two-headed gamma camera
employing a 20% window centred over a photo peak of 140 keV.
Patients were scanned in supine position and images were
obtained from the right anterior oblique to the left posterior
oblique position with 64 steps lasting 20 seconds each and gated
acquisition with 12 frames per RR interval. The matrix resolution
was 64664616 pixels. All images were reviewed by at least two
specialists in nuclear medicine with subspecialty in analyses of
MPI. No automated-only analyses were used.
Myocardial perfusion was categorized as abnormal if a
reversible and/or irreversible perfusion defect was shown
involving at least ten percent of the myocardium of the left
ventricle and if two or more of 20 segments were hypoperfused
more than 2.5 SD below normal. The MPI was also categorized as
abnormal when post stress EF and/or end systolic volume (ESV)
index were below lower normal limit (EF ,51% in men and
,43% in women, and ESV index ,39 ml/m
2 in men and
,27 ml/m
2 in women [41]. ESV index was only evaluated in
individuals with EF below lower normal limit.
Statistical analyses
For continuous variables, comparisons between the groups of
patients with normal or abnormal MPI were performed by
independent samples t-test (Student’s t-test), including Levene’s
test for equality of variance. Mann-Whitney test was used if
Levene’s test for equality of variance was significant, or if a
variable exhibited a clear non-Gaussian distribution. For categor-
ical variables the x
2-test was used. Patterns of distribution were
examined by histograms and P-Plot analyses. If the distribution is
the non-Gaussian a test of statistical (log-) normality was
performed.
Concentrations of NT-proBNP, YKL-40, IL-6, MMP-9 and
hsCRP were skewed and were logarithmically transformed before
further statistical analyses. Subgroup analyses were made for each
gender. Since the objectives of the study was to discriminate
individuals with a normal MPI and due to an expected low
frequency of perfusion defects in this small sample size, analyses of
the different types of perfusion defects were mot performed. Data
are presented as mean 6 SD or as median and interquartile range
(IQR).
Analyses of associations were performed using linear regression
models with abnormal MPI as dependent variable. Univariate
analyses of correlations of either one of the biomarkers NT-
proBNP, YKL-40, IL-6, MMP-9 and hsCRP with an abnormal
MPI were performed prior to multivariate analyses. Multivariate
analyses including age, gender, smoking, cholesterol level, known
CAD, EF, hypertension or diabetes were performed for biomark-
ers with significant outcome in the univariate analyses. ROC-
curve analyses of NT-proBNP values for the prediction of a
normal MPI was made to assess the NT-proBNP screening cut off-
concentration at which a sensitivity of 95% for a normal MPI was
achieved. Confidence intervals for sensitivity, specificity and
negative predictive values were calculated according to Mercaldo
NT-proBNP as a Screening Tool
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14196et al [42]. All p-values were calculated as two-sided, and a p-value
,0.05 was considered significant. Analyses were made with the
statistical software package SPSSH 15.0 (SPSS inc., Chicago, Il,
USA) and SASH 9.0 (SAS, Cary, NC, USA).
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